Oruka Therapeutics may sell up to $500,000,000 of common stock through TD Cowen, with proceeds intended for general corporate purposes including Research and Development and working capital. The prospectus illustrates 4,768,262 shares sold at $104.86 per share, resulting in immediate dilution of $80.57 per share for new investors.
Key Highlights
- New investors face immediate dilution of $80.57 per share under the offering illustration.
- Oruka Therapeutics plans to direct net proceeds toward general corporate purposes, research and development and working capital.
- The filing states that actual share issuance will depend on the prices achieved in sales.
Oruka Therapeutics, Inc. (NASDAQ: ORKA) may sell up to $500,000,000 of common stock through TD Cowen, acting as agent or principal. The at-the-market program allows sales from time to time at prices and on terms determined by market conditions. The actual number of shares issued will depend on the prices achieved in sales.
Up To $500M Stock Sale
The common stock carries a $0.001 Par Value per share. Oruka Therapeutics entered into the sales agreement with TD Securities (USA) LLC, also known as TD Cowen, on October 3, 2025, and amended it on August 21, 2026.
Assumed Price Sets Dilution
The company projects up to 65,838,149 common shares outstanding after the offering under that assumption. The calculation starts with 61,069,887 shares outstanding as of June 30, 2026.
It also excludes 5,706,188 shares issuable upon exercise of pre-funded warrants.
Proceeds Fund R&D, Working Capital
Those purposes include research and development and working capital.
Peers Moving on This News
- Caris Life Sciences Inc (NASDAQ: CAI) little changed
- CG Oncology, Inc. (NASDAQ: CGON) down 0.6%
- Scholar Rock Holding Corporation (NASDAQ: SRRK) little changed




Please wait processing your request...